Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy.
Crucitta S, Restante G, Del Re M, Bertolini I, Bona E, Rofi E, Fontanelli L, Gianfilippo G, Fogli S, Stasi I, Ghilli M, Fontana A, Danesi R. Crucitta S, et al. Among authors: gianfilippo g. Cancer Chemother Pharmacol. 2019 Dec;84(6):1219-1227. doi: 10.1007/s00280-019-03933-z. Epub 2019 Sep 16. Cancer Chemother Pharmacol. 2019. PMID: 31529205
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M, Bertolini I, Crucitta S, Fontanelli L, Rofi E, De Angelis C, Diodati L, Cavallero D, Gianfilippo G, Salvadori B, Fogli S, Falcone A, Scatena C, Naccarato AG, Roncella M, Ghilli M, Morganti R, Fontana A, Danesi R. Del Re M, et al. Among authors: gianfilippo g. Breast Cancer Res Treat. 2019 Nov;178(1):57-62. doi: 10.1007/s10549-019-05365-y. Epub 2019 Jul 26. Breast Cancer Res Treat. 2019. PMID: 31346846
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Del Re M, Petrini I, Mazzoni F, Valleggi S, Gianfilippo G, Pozzessere D, Chella A, Crucitta S, Rofi E, Restante G, Miccoli M, Garassino MC, Danesi R. Del Re M, et al. Among authors: gianfilippo g. Clin Lung Cancer. 2020 May;21(3):232-237. doi: 10.1016/j.cllc.2019.10.003. Epub 2019 Oct 13. Clin Lung Cancer. 2020. PMID: 31735523
Circulating biomarkers of response to immunotherapy in cancer treatment.
Del Re M, Gianfilippo G, Crucitta S, Addeo A, van Schaik RH, Danesi R. Del Re M, et al. Among authors: gianfilippo g. Pharmacogenomics. 2019 Dec;20(18):1247-1249. doi: 10.2217/pgs-2019-0117. Epub 2019 Nov 6. Pharmacogenomics. 2019. PMID: 31691637 No abstract available.
Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers.
Rofi E, Del Re M, Arrigoni E, Rizzo M, Fontanelli L, Crucitta S, Gianfilippo G, Restante G, Fogli S, Porta C, Danesi R, Schmidinger M. Rofi E, et al. Among authors: gianfilippo g. Crit Rev Oncol Hematol. 2020 Oct;154:102891. doi: 10.1016/j.critrevonc.2020.102891. Epub 2020 Apr 25. Crit Rev Oncol Hematol. 2020. PMID: 32340783 Free article.
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer.
Del Re M, Crucitta S, Sbrana A, Rofi E, Paolieri F, Gianfilippo G, Galli L, Falcone A, Morganti R, Porta C, Efstathiou E, van Schaik R, Jenster G, Danesi R. Del Re M, et al. Among authors: gianfilippo g. BJU Int. 2019 Oct;124(4):693-700. doi: 10.1111/bju.14792. BJU Int. 2019. PMID: 31055861
15 results